Current Report Filing (8-k)
May 09 2019 - 1:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2019 (May 8, 2019)
FUSE MEDICAL, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-10093
|
|
59-1224913
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
1565 North Central Expressway
Suite 220
Richardson,
Texas
|
|
75080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants Telephone Number, including area code: (469)
862-3030
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock
|
|
FZMD
|
|
OTCPink
|
On May 8, 2019, Fuse Medical, Inc., a Delaware corporation (the
Company
), issued a press release, attached hereto as
Exhibit
99.1
, regarding (1) the filing of its quarterly report on Form
10-Q
for the fiscal quarter ended March 31, 2019 with the Securities and Exchange Commission and (2) its earnings for the same
period.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
|
FUSE MEDICAL, INC.
|
|
|
By:
|
|
/s/ William E. McLaughlin, III
|
|
|
William E. McLaughlin, III
|
|
|
Senior Vice President,
Chief Financial
Officer and Director
|
Date: May 9, 2018
Fuse Medical (PK) (USOTC:FZMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fuse Medical (PK) (USOTC:FZMD)
Historical Stock Chart
From Sep 2023 to Sep 2024